GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Float Percentage Of Total Shares Outstanding

ADAG (Adagene) Float Percentage Of Total Shares Outstanding : 75.13% (As of Mar. 31, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adagene's float shares is 35.39 Mil. Adagene's total shares outstanding is 47.11 Mil. Adagene's float percentage of total shares outstanding is 75.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adagene's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adagene's Institutional Ownership is 32.58%.

Adagene Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Adagene's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=35.39/47.11
=75.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
AVTE IGMS VERU CLSD IVVD VTGN ABOS MNOV CABA TCRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Website
https://www.adagene.com
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.